News from the FDA/CDC

Substance use treatment cost $34 billion in 2014


 

Total spending on the treatment of substance use disorder reached $34 billion in 2014, with outpatient care taking the largest share, according to the National Center for Health Statistics.

That $34 billion represents an increase of 273% from the $9.1 billion spent in 1986 and a considerable shift in the distribution of spending over the last 30 years. In 1986, the largest share of spending – 50%, or $4.6 billion – for substance use disorder went toward inpatient care and only $2.4 billion (27%) was used for outpatient care. In 2014, outpatient treatment of substance use disorder had a 40% share ($13.6 billion) of all spending, and inpatient care was down to 19% ($6.4 billion), the NCHS reported in “Health, United States, 2016.”

Distribution of U.S. substance use disorder expenditures
The second-largest segment of expenditures in 2014 went to residential care at 27%, which works out to almost $9.3 billion, followed by inpatient care, insurance administration at 8% ($2.8 billion), and retail prescription drugs at 5% ($1.8 billion). In 2004 and earlier, use of retail prescription drugs for the treatment of substance use disorder was almost nonexistent, totaling only $11 million in 2004 and $5 million in 1998. In 2009, however, spending on retail prescription drugs was $890 million, as shown by data from the Substance Abuse and Mental Health Services Administration’s Behavioral Health and Spending Use Accounts.

Since methadone is not considered a retail drug by SAMHSA, it is classified under specialty substance use disorder treatment centers, which are included in the estimate for outpatient care, the NCHS noted.

Recommended Reading

Follow five tips to mitigate opioid prescribing risks
MDedge Internal Medicine
New on the streets: Drug for nerve pain boosts high for opioid abusers
MDedge Internal Medicine
Endo removes Opana ER from market
MDedge Internal Medicine
Opioid prescribing drops nationally, remains high in some counties
MDedge Internal Medicine
As designer drugs multiply, toxicologists spring into action
MDedge Internal Medicine
Tramadol extended-release treated opioid withdrawal symptoms better than clonidine
MDedge Internal Medicine
Nearly half of patients who stop taking opioids for 6 months resume use later
MDedge Internal Medicine
What works and what doesn’t in treating binge eating
MDedge Internal Medicine
Physician liability in opioid deaths
MDedge Internal Medicine
Report: Opioid epidemic fight must increase substantially and immediately
MDedge Internal Medicine